RedHill Biopharma to Present at German Equity Forum 2020
13 nov. 2020 07h00 HE
|
RedHill Biopharma Ltd.
TEL AVIV, Israel and RALEIGH, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...
RedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 2020
05 nov. 2020 07h00 HE
|
RedHill Biopharma Ltd.
TEL AVIV, Israel and RALEIGH, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...
RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
08 oct. 2020 10h30 HE
|
RedHill Biopharma Ltd.
RedHill obtains Israel rights to Movantik® from AstraZeneca, giving RedHill global rights, excluding Europe and Canada--Movantik approved for opioid-induced constipation in Israel under the brand name...
RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi®
28 juin 2018 09h00 HE
|
RedHill Biopharma Ltd.
RedHill has been granted the exclusive right to co-promote Mytesi® (crofelemer 125 mg delayed-release tablets) in the U.S. to certain gastroenterologists and primary care physicians for the approved...
RedHill Biopharma Reports 2014 Fourth Quarter and Year-End Financial Results
26 févr. 2015 07h50 HE
|
RedHill Biopharma Ltd.
Key Highlights Include:
Strong cash position of over $34 million, following completion of a $14.4 million U.S. public offering in February 2015
With three ongoing Phase III clinical...
RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation
27 févr. 2014 08h01 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) and RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) today announced that they have entered into an...
RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results
25 févr. 2014 08h00 HE
|
RedHill Biopharma Ltd.
2013 Key Highlights Include:
Strong cash position of over $34 million, as of February 2014, following two private placements in early 2014 and the exercise of warrants, including by directors...